- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03416907
Informed Consent Formats by Information Preference and Priority
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15213
- Carnegie Mellon University
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- 18 Years Old or Older
- Read and agreed to informed consent
- Indicated desire to participate
- Diagnosed with asthma
- US resident
Exclusion Criteria:
- Participants from whom we receive multiple responses will be dropped from analysis (but will be compensated for participation)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Original
Participants will review the full-length, original consent form for the clinical trial.
|
Participants will review the full-length, original consent form for the clinical trial.
|
|
Experimentell: Shortened
Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
|
Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
|
|
Experimentell: Reordered
Participants will review a reordered, shortened consent form.
This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
|
Participants will review a reordered, shortened consent form.
This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
|
|
Experimentell: Highlighted
Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
|
Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
|
|
Experimentell: Interactive
Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided.
The landing page includes the introductory section.
|
Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided.
The landing page includes the introductory section.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Score for high impact questions
Tidsram: through study completion, an average of 30 minutes
|
Sum of correct answers (T/F) for any item relating to material that was rated as 50 or higher on impact on willingness to enroll in a previous study.
|
through study completion, an average of 30 minutes
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Score for low impact questions
Tidsram: through study completion, an average of 30 minutes
|
Sum of correct answers (T/F) for any item relating to material that was rated as 49 or lower on impact on willingness to enroll in a previous study.
|
through study completion, an average of 30 minutes
|
|
Total score for all questions
Tidsram: through study completion, an average of 30 minutes
|
Sum of correct answers (T/F) on full knowledge test.
|
through study completion, an average of 30 minutes
|
|
Interaction effect of format and importance on likelihood of correct answer
Tidsram: through study completion, an average of 30 minutes
|
Interaction effect in a logistic regression predicting a correct answer, based on the format of the consent form and the importance of the answer.
|
through study completion, an average of 30 minutes
|
|
Scores for different information categories
Tidsram: through study completion, an average of 30 minutes
|
Sum of correct answers (T/F) for each of the 20 information categories
|
through study completion, an average of 30 minutes
|
|
Effect of location on score
Tidsram: through study completion, an average of 30 minutes
|
Logistic regression coefficient of likelihood of predicting a correct answer, based upon the location on which the sentence appeared--uses only the shortened, and the reordered conditions.
Note that sentences appearing in the introduction (which is the first section of all treatments) must be dropped, as there will be no variation in location.
|
through study completion, an average of 30 minutes
|
|
Decision to enroll
Tidsram: through study completion, an average of 30 minutes
|
Likert measure of participants hypothetical decision to enroll in the study
|
through study completion, an average of 30 minutes
|
|
Confidence in enrollment decision
Tidsram: through study completion, an average of 30 minutes
|
Likert measure of participants confidence in hypothetical decision to enroll in the study
|
through study completion, an average of 30 minutes
|
|
Satisfaction with consent structure
Tidsram: through study completion, an average of 30 minutes
|
Likert measure of participants satisfaction with the consent form
|
through study completion, an average of 30 minutes
|
|
Perception of investigator concern for well being
Tidsram: through study completion, an average of 30 minutes
|
Likert measure of participants belief in the investigator's concerns for the participant's well-being
|
through study completion, an average of 30 minutes
|
|
Perception of investigator transparency
Tidsram: through study completion, an average of 30 minutes
|
Likert measure of participants belief that the investigator is trying to communicate information about the trial accurately
|
through study completion, an average of 30 minutes
|
|
Participant's probability estimate of the likelihood that the treatment would help control their asthma
Tidsram: through study completion, an average of 30 minutes
|
Survey question of the following form: 'If you enrolled in the trial described in the consent form, what is the probability that the treatment could help control your asthma better, where 0% means "no chance at all of helping" and 100% means "would definitely help"?' Participants provided with drop-down menu including values from 0% to 100% in increments of 1%. |
through study completion, an average of 30 minutes
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Participant's free-response text describing what was learned from reading the informed consent document
Tidsram: through study completion, an average of 30 minutes
|
Survey question of the following form: "What are some of the key things you learned from reading the informed consent document?" Participants are then provided with an free-response text box where they are allowed to enter whatever text they want, as long as they enter some text. These responses will be coded by two independent coders, blinded to the treatment arms, using an emergent coding system to identify different topics that participants may raise. |
through study completion, an average of 30 minutes
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- STUDY2017_00000268
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Original consent form
-
University of PennsylvaniaAvslutadKritisk sjukdomFörenta staterna
-
University of FloridaEunice Kennedy Shriver National Institute of Child Health and Human Development... och andra samarbetspartnersAvslutadKommunikationsforskning | Attityd hos hälsopersonal | Förtroende | Attityd till datorer | Relationer mellan forskare och ämneFörenta staterna
-
Yale UniversityAvslutadPatientcentrerad resultatforskningFörenta staterna
-
Hannover Medical SchoolFresenius KabiAvslutadSepsis | Systemiskt inflammatoriskt svarssyndrom | Kritisk sjukdom | VuxenTyskland
-
Oslo University HospitalUniversity of Oslo; Norwegian National Advisory Unit on Rare Disorders... och andra samarbetspartnersAnmälan via inbjudanÄrftlig motorisk och sensorisk neuropati | Polyneuropatier | Charcot-Marie-ToothNorge
-
Ethicon, Inc.RekryteringHemostas | Hemostatiska teknikerFörenta staterna, Nederländerna
-
Dr. Reddy's Laboratories LimitedOkänd
-
Sheffield Hallam UniversityUniversity of Leeds; Nimble Science Ltd.; BiotifulRekryteringHjärt-kärlsjukdomar | Sova | Tarmmikrobiom | LDL-kolesterol | Kognitiv funktion och humörStorbritannien
-
Merck Sharp & Dohme LLCAktiv, inte rekryterande
-
Jules Bordet InstituteRoche Pharma AGAvslutad